Palatin Technologies Inc New (PTN) News

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint...

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177

Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1...

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update PR...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement

Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement PR...

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide

Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide PR...

Palatin Provides Update on Anticipated 2025 Corporate Milestones

Palatin Provides Update on Anticipated 2025 Corporate Milestones PR Newswire CRANBURY, N.J., Jan. 28, 2025...